Following her insightful SCItalk on Diversity, Equality and Inclusion, Ijeoma Uchegbu, Chair in Pharmaceutical Nanoscience at UCL's School of Pharmacy speaks with Darcy Phillips.

Tell us about your career path to date.

I trained as a pharmacist and then did a PhD at the School of Pharmacy on drug delivery using nanosystems. After about two years of postdoctoral scientist work, I was appointed to a lectureship at the University of Strathclyde in Glasgow. After five and a half years, I was appointed to a professorship in 2002. I then joined the School of Pharmacy as a Professor of Pharmaceutical Nanoscience in 2006 and UCL in 2012.

My work has focused on understanding how drug transport may be controlled in vivo using nanoscience approaches. I co-founded Nanomerics Ltd. with my long-term collaborator – Professor Andreas G. Schätzlein – and next year will see Nanomerics take the technologies developed in academia into clinical testing. This is a huge milestone for our small company and for us personally. I liken this milestone to sending your only child off into the big wide world, and so we are understandably nervous and excited in equal measure!

Science was a refuge for me as I moved countries as a teenager – from London, the city of my birth, to a small town in Nigeria called Owerri. Science subjects were the only subjects that were common on the secondary school curricula of both countries. I really had no other option. I fell in love with science because it was familiar.

Which aspects of your work motivate you the most?

The joy of discovery really gives one a high and this is what I enjoy the most. Validation of one’s discoveries by other members of the scientific community cements the high and when one’s ideas are evidenced first by experimentation and then appreciated by one’s peers, there is no other feeling in the world quite like it.

What has been your proudest achievement?

Getting my professorship so soon after my appointment to a lectureship at the University of Strathclyde is up there with the greatest moments of my career, as is bringing up my daughters at the same time. Oh dear – there are far too many moments to mention, to be honest! Every day I don’t get a rejected paper or grant is really a proud day. Rejections are 90% of a scientist’s life.

You spoke recently at our SCItalk on diversity, equality and inclusion and the importance of data. Could you give us a summary on why this is so important?

To produce good quality science outputs with the maximum impact we need a variety of individuals asking and answering the most profound of research questions. We need more data on diseases and conditions that affect women and more data on the genomics affecting the global southern majority. We need answers to the pressing questions on health outcomes in the poorest in our UK society. Well, you get the picture. We need high quality data on these largely forgotten issues.

What do you think are the next key steps to making STEM more diverse and inclusive?

We first need to recognise that a problem exists. This is the first step. The data on underrepresentation needs to be at the forefront of our thinking when we are making decisions. We need funders to acknowledge the deficit in the current ways of doing things and then commit to act appropriately. The oddest thing about a skewed and unequal system is that we all lose out when there are entrenched inequalities. Even those that think that they are gaining from the current system are not.

Batteries are a critical enabler for reaching net zero. As their importance increases, so does the need to better understand how they operate.

Mel Loveridge, Associate Professor (Reader) at Warwick University, gives an overview of the complexities of battery science and how she is working to bring increased understanding to a wider audience.

As the role of batteries has an increasing presence in everyday life, there is now a focus on battery forensic science and advanced characterisation methods – a critical part of understanding the life of a battery, its safety aspects and its cycle life or lifespan.

This forensic analysis and advanced characterisation is the core part the work carried out by Associate Professor (Reader) Mel Loveridge at Warwick University, who says: ‘The aim is to firstly understand and identify early-stage signatures of battery degradation, and ultimately to unearth the root causes and propagation of failure in lithium-ion battery (LIB) components.’

Since LIBs were commercialised in 1991, the electronic devices that use LIBs have diverged considerably, with much larger format batteries now required to electrify transport. This is a critical enabler that is needed if the world is to reach net zero.

‘Much research is focused on developing materials with higher energy and power density to effectively do this, and this is why battery safety considerations are more paramount now than ever,’ says Loveridge.

‘It is only by understanding how materials (electrodes and electrolyte) degrade using sophisticated forensic techniques, that we can feedback into the design of better, safer, more robust and stable components that will last longer,’ she adds.

This is key for the continued range and power improvements in electric vehicles, where ultimately everyday users will benefit from advances in battery materials and manufacturing processes.

Developing characterisation capabilities

This understanding requires effective characterisation capabilities to look at the chemical and structural dynamics that occur inside the battery as it ages. This can be accomplished destructively by autopsy when the battery has reached the end of its life (ex-situ) or done in real time whilst the battery is going through charge-discharge cycling (operando).

Because of the small size of the lithium atom, specialised X-ray based microscopy and other techniques are required to detect and map it. Fully understanding the complex journey of the lithium ions during battery operation is still challenging for the battery community.

Pictured above: A cathode particle. Copyright WMG

To facilitate this greater understanding, WMG was recently awarded an equipment grant to build the UK’s first multi-modal microscope platform with a plasma focused ion beam sectioning device (deliberately designed with batteries in mind, unlike other systems in existence). This includes a time-of-flight mass spectrometer to enable 3D detection and mapping of lithium. The integrated analytical platform will allow us to understand micro to meso scale structure and chemical dynamics over broad length and time scales.

The recent EU 2030 roadmap (Battery 2030+) stated “The accelerated discovery of stabilised battery materials requires special attention to the complex reactions taking place at the many interfaces within them.” Also awarded was a Lord Bhattacharyya PhD project to work on the commissioning and further development of this characterisation platform.

Breaking down the complexity for government and media

The work is highly challenging and riddled with complexities, but it has attracted significant media and government interest in the last decade and Loveridge has been one of the voices providing accessible, expert insight on a range of media platforms.

‘I have been fortunate to be interviewed for BBC2, Channel 4 and BBC Radio 4, describing how batteries work. I have also participated in energy-related panel discussions with the House of Lord’s Science & Technology Committee and the House of Commons Shadow Cabinet. Prior to this, an article I published on the temperature implications of wireless charging for a mobile phone battery was summarised in a feature in The Telegraph.’

The important work being carried out in battery forensic analysis is set to shape the future of battery technology.

We catch up with Zoë Henley, a Medicinal Chemistry Lead at GSK and recent recipient of a Rising Star Award in the category of Science & Engineering

Tell us about your career path to date.

Growing up, I loved science and have early memories of playing with my beloved chemistry set. However, it wasn’t until my A-levels that I knew I wanted to study chemistry at university. I had an inspiring chemistry teacher who supported me to apply, and I ultimately gained a first-class MSci chemistry degree from the University of Bristol.

I joined GSK as an Associate Scientist in 2006 and in my early career I was focused on identifying new molecules to treat respiratory diseases. As a chemist, I use my synthetic and medicinal chemistry skills to identify potential drug candidates, one of which reached Phase 2 clinical trials in patients for the treatment of Chronic Obstructive Pulmonary Disease, which is a life-threatening lung condition with no current cure. I have also led discovery efforts on early-phase research projects to validate the exact role a potential therapeutic target plays in a disease, which is critical for initiating a drug discovery programme.

Through my work, I developed deep technical skills in inhaled drug design and was appointed chair of a technical network for inhaled drug discovery programmes within GSK.

Alongside my work in the laboratory, I also developed my technology skills to become the lead user in Europe for drug compound design and data analysis software.

I was promoted to a Scientific Investigator in 2013 and achieved my PhD in 2014, through a collaborative programme between GSK and the University of Strathclyde. In September 2021, I was promoted to Team Leader.

Over the period I have been a team leader, I have supported 12 scientists and have had the opportunity to mentor graduate chemists and supervise one-year industrial placement students. I am currently a project Medicinal Chemistry Lead and have three direct reports who I support in their professional and scientific development at GSK.

‘I am passionate about science and the job that I do, and am committed to being an advocate for female leaders in chemistry.’ Image: Zoë Henley

Which aspects of your work motivate you the most?

I find the job of a medicinal chemist fascinating and highly rewarding. As a chemist, I have the opportunity to make the molecule that becomes a medicine to help patients, and this is my greatest motivation. Medicinal chemistry is a fast-paced, constantly evolving field that requires diverse skill sets. I find it refreshing to work within a diverse team, in particular working internationally across our global organisation, where I have had experience of working with colleagues across scientific disciplines and from different cultures and backgrounds who bring varied perspectives.

You were recently recognised with a Rising Star Award in the category of Science & Engineering, do you have any advice for anyone starting out their career in this field?

I am passionate about science and the job that I do, and am committed to being an advocate for female leaders in chemistry. For those starting out in this field, I would encourage them to follow their hearts and make well-informed career and personal choices to fulfil their dreams. Whenever I have had decisions to make, I have relied on close friends and mentors for advice, and I would encourage others to identify role models and seek their mentorship. I would also advise pursuing anything you feel passionate about. This might mean, for example, developing a new skill or gaining deeper expertise.

‘GSK as an organisation is highly supportive of flexible working, and within my own department I have continually had support for my professional development, in particular when I returned to work after one year maternity leave.’ Image: Zoë Henley

You’ve been working at GSK for a number of years now – can you tell us a bit more about how they’ve supported you in your career and allowed you to balance this with family life?

Throughout my career at GSK I have had so many opportunities to develop professionally and personally. Alongside continuously developing my technical skills, I have been able to carry out a PhD whilst still a full-time employee of GSK, participated in STEM outreach activities, had supervisory responsibility for both GSK employees and PhD students on collaborative projects, and I have been asked to take leadership roles in many different settings.

In 2019, I became mum to my son Sam, and I have since progressed my career whilst working part-time. I had very few female role models until I came to GSK, where the number of female chemists is high and there were many who had families and successful careers, which gave me confidence that I could have the same.

GSK as an organisation is highly supportive of flexible working, and within my own department I have continually had support for my professional development, in particular when I returned to work after one year maternity leave. My manager was highly supportive of my continued trajectory towards taking a leadership role and supported me in applying for a Deep Dive Career Programme at GSK, which is a competitive programme for future leaders who want to actively shape their career journey.

The programme allowed me to set out a detailed personal development plan and helped to expand my network. The leaders of my department also offered me managerial responsibilities, and this ultimately empowered me to apply for and achieve a Team Leader position.

I have a successful career/family life and aim to give other chemists the confidence that they can achieve the same.

If you'd like to hear more from inspiring female scientists like Zoë take a look at our upcoming SCItalk on Wednesday 27 September: Women in STEM: Better Science and a Better Workplace for Everyone.

Accelerating the transition to a sustainable global energy system

Welcome to the first in this series from the SCI Energy Group – we’ll be blogging regularly on topics of broad interest across the energy spectrum.

Andy Walker, Chair of the SCI Energy Group.

I’m Andy Walker, and I have the privilege of chairing the Energy Group, which comprises members drawn from industry, research institutes, universities, energy policy bodies, R&D organisations and scientific publishers. We meet regularly to discuss and organise events around the changing energy landscape, exploring challenges and opportunities associated with the clean energy transition.

We inform and influence climate change dialogue and policy in the UK and further afield, by taking a fact-based approach to the challenges and potential solutions, with the ultimate aim of making the global energy system sustainable. We do this by bringing together experts, influencers and other interested parties from across the technology, social science and policy landscape within industry, academia and government. In this way, the SCI Energy Group offers thought leadership, insight and debate around the clean energy transition.

Recently, the Energy Group Committee visited Imperial College London and were given a fascinating tour of the carbon capture and storage pilot plant, which Committee member Alex Bowles had very kindly organised. This was a really interesting visit, hosted by Dr Colin Hale and several enthusiastic and knowledgeable chemical engineering students, focused on the critical role that the capture and long-term storage (and utilisation) of CO₂ will play within the clean energy transition. We learned that carbon capture utilisation and storage (CCUS) can play four critical roles in the transition to net zero:

1. Tackling emissions from existing energy assets, for example by retrofitting existing fossil fuel-based power and industrial plants, by capturing the CO₂ emissions emitted during these processes.
2. As a solution for sectors where emissions are hard to abate, such as the in-process emissions during cement manufacture (one of the largest industrial sources of CO₂ today).
3. As a platform for clean hydrogen production – almost all of the 90 million tonnes of hydrogen generated today is via methane steam reforming, which emits around 10 tonnes of CO₂ for every tonne of hydrogen produced.
4. Removing CO₂ from the atmosphere to balance emissions that cannot be directly abated or avoided (so-called direct air capture, DAC).

The International Energy Agency (IEA) estimates that the amount of CO₂ captured and stored annually in their Sustainable Development Scenario rises to around 9.5 Gt per year by 2070, with another 0.9 Gt CO₂ captured and used to make, for example, fuels and chemicals. (Note that a Gigatonne (Gt) is one billion metric tonnes).

IEA, Growth in world CO₂ capture by source and period in the Sustainable Development Scenario, 2020-2070, IEA, Paris. Licence: CC BY 4.0

The Energy Group plans to visit several other sites of interest in the coming months, including Drax and the Energy Innovation Centre in Birmingham, so look out for updates from these future visits.

Our next blog will relate to a recent workshop on Energy Storage, which we organised with strong support from Innovate UK/Knowledge Transfer Network. We brought in representatives from industry, academia, government and the finance sector to discuss this broad topic and to identify the key challenges, as well as outline some key policy questions for the government.

We chose this topic because energy storage is a critical part of the clean energy transition, as the world moves towards an increasing dependency on renewable sources of energy, which are inherently intermittent, yet it doesn’t receive enough attention and support from governments around the world. We’re sure you’ll find the outputs from this workshop very interesting!

Creating a paper pulp bottle that holds different liquids was a challenge that led BASF to join forces with Pulpex. Using sustainable chemistry the partners came up with an award-winning formula.

• Vikki Callaghan, Packaging Project Manager, BASF plc

• Tony Heslop, Senior Sustainability Manager, BASF plc

• Scott Winston, CEO Pulpex Ltd

Could you start by explaining how the collaboration and the idea for the product came about?

Vikki: We had an existing relationship with Diageo. BASF and The Innovation Team at Diageo had worked on other projects addressing packaging needs. When the team had this idea for an innovative packaging solution they came to us. The challenge put to us was ‘Do you have the chemistry that will hold many different liquids in a paper pulp bottle?’ I love a challenge and was excited to get talking.

Scott: Having worked with BASF before, they were our natural choice to explore this conundrum. Diageo had the idea and an early proof-of-concept of a paper bottle, but it wasn’t utilising sustainable chemistry. The intellectual property was in place but the transformation of scientific proof-of-principle to scaled commercialised technology wasn’t something that could be done alone. The partnership with BASF naturally continued into Pulpex as it formed and continued to grow, remarkably, throughout the Covid-19 lockdown. BASF’s corporate purpose to create chemistry for a sustainable future was intrinsically aligned to meet our need to deliver a commercialisable product that could be produced at scale.

Tony: Following that first call in November 2019, we got together a couple of weeks later and enjoyed an intense deep dive workshop. This was going to take some time but if successful we knew this could be an impactful innovation. We set to work!

Testing out their bottle in the lab. Image courtesy of Pulpex Ltd.

What hurdles did you overcome in the development of the material?

Tony: The obvious hurdle was the pandemic. There were two years between our first and second face-to-face meeting. My initial thought was how do you drive an innovation process when you can’t get together. Surely constructive and productive collaboration isn’t possible? In fact, the inability to travel meant that we could talk more frequently despite our different geographical locations. Once we’d set up weekly online meetings, which evolved into smaller specialist break out groups, the process actually had many positives and the relationships, as well as the innovation, flourished.

Vikki: Of course, as with any innovation, we experienced technical challenges, too. There was no overall solution because we were looking at very diverse requirements and specifications. Different brand owners with different liquids meant there were many considerations and customised solutions required.

Sustainable packaging is a growing market with new products being launched. Can you explain where your product fits in and how is it different from similar materials?

Scott: Pulpex recognises the need to balance three critical aspects. Firstly, new packaging must continue to deliver established brand equity and meet consumer expectations on quality; secondly, any new packaging must technically deliver on performance through the supply chain starting with filling infrastructure compatibility and through distribution and critically, at end-of-life the packaging must be recyclable in existing infrastructure from collection to enable circularity, or where it does unfortunately escape to the environment, it must degrade and not leave an unintended legacy.

Vikki: The resulting fibre bottle is lightweight and offers brand owners a sustainable, environmentally-friendly alternative to plastic and glass bottles.

The final product. Image courtesy of Pulpex Ltd.

What are the main markets for the packaging? Are you able to comment on customers already using your product?

Tony: The innovation will be aimed at brand owners who want to have an alternative sustainable type of packaging, a product that is suitable for ‘on the go’ and that is easily recyclable through existing waste streams. The technology will hold a range of liquids from alcohol and detergent to shower gel, ketchup and engine oil.

Scott: Trials of the finished product have already started to take place with the most recent being at a corporate five-a-side football tournament at Wrexham AFC in May, where several hundred bottles were put to the test working with Severn Dee Water. Branded especially for the event and designed as a keepsake, the feedback from the public was resoundingly positive and it was great to see our bottles in action supporting those on the pitch.

What are the next steps for the BASF/Pulpex collaboration?

Scott: Having developed such a sustainable alternative packaging, our continuing sprint is scaling up! The technology has been developed and we are expecting to have bottles on shelves soon.

Vikki: We will have our ongoing quest of looking to hold a vast range of liquids and for different brand owners. We will have customised solutions, in different sizes, different shapes… the innovation and collaboration continues.

BASF and Pulpex won the SCI Innovation Enabled by Partnership Award 2023. Image credit: Andrew Lunn Photography

Links to previously published articles and videos (BASF/Pulpex/SCI)

• BASF May 2023 – SCI Award
• BASF August 2021 – Collaboration with Pulpex
• SCI News May 2023 – SCI Award
• Pulpex May 2023 – SCI Award
• Pulpex video

CCU International will supply its carbon capture and refinement system to Flue2Chem – a project led by SCI and Unilever which aims to convert industrial waste gases to create more sustainable consumer products. We caught up with CCU International CEO, Beena Sharma, to talk about her career path, motivations and challenges.

Tell us about your career path to date

I joined the Oil & Gas industry after university and began my career as a behavioural safety specialist, specifically for the construction phase of oil and gas projects. Soon after I joined the industry, I was assigned to an LNG plant in Nigeria for training and experience and eventually ended up at a gas plant in Norway before I returned to the UK. With both a psychology and training background I found myself working within a health, safety and environmental remit for various industries including healthcare, construction, manufacturing, and even the tobacco industry.

Beena and colleague at a gas plant in Norway, 2004. Image credit: Beena Sharma

What made you want to work in science and the environmental technology sector in particular?

When I moved to Scotland six years ago it gave me the opportunity to explore the ‘E’ in Health, Safety and Environment further, which was an area that I was always interested in but rarely got the attention it deserved in the industries I worked in. I volunteered on a Scottish climate change project, and this led me to think more deeply about the scientific and technological advances that were needed to achieve net zero by 2045 in Scotland. I knew this was a huge challenge with education, and changes in habit alone could not solve it.

I began to research solutions for hard-to-abate industries and areas that were a challenge to decarbonise, and set up my first business focused on a novel approach to insulating legacy buildings. I then worked on setting up a group of companies that included a solar PV installation company as well as a cleantech business that utilised an electrolysis technology to ozonate tap water for disinfection.

I was invited by my now business partner to help launch a biotechnical business that could create a circular food economy, taking food waste and creating microalgae for use in industries such as cosmetics, pharmaceuticals, and animal feed. This business incorporated 4 technologies, one of which was carbon capture. After some discussion with potential investors, it became clear that there was a huge interest and demand for carbon capture solutions. This led the team to decide to spin out CCU International as a separate entity and speed up the commercialisation of the technology which had been in development at the University of Sheffield under the lead of Peter Styring, Professor of Chemical Engineering and Chemistry.

Which aspects of your work motivate you the most?

The aspects of what I do that motivates me the most is the educational role that I play as the CEO of the business. I am regularly invited to speak on panels, podcasts, webinars and at conferences to share my knowledge with an industry that is transitioning and eager to learn, grow and incorporate new ways of thinking and doing things. It is extremely rewarding to see that people have come away from listening to me with a new perspective and being inspired to go away, take that learning, incorporate it in their ways of working and become innovators themselves.

According to the UN, carbon capture will be a key technology in achieving net zero. It is extremely rewarding to know that the CCU International technology will be a major contributor to this goal and that we can enable decarbonisation with the technology usage across multiple industries, both large and small, which otherwise would not have been possible.

What have been the biggest challenges for you as an entrepreneur?

As an entrepreneur my biggest challenge has been establishing myself in an industry and environment that is not well represented by women, and in particular women of colour. Often, it comes as a surprise to many that I would be heading up such a business and unfortunately many biases still exist within all genders and backgrounds. It makes it that extra bit harder and there can be a requirement to prove oneself as credible through knowledge or capability before the respect is given.

Image credit: Beena Sharma

The other big challenge has been around the education we provide for all our stakeholders. Innovation is not always welcome, especially in an industry or area where it may seem innovation is not needed. As the saying goes, ‘if it’s not broke, don’t fix it’, so stakeholders tend not to realise there is a problem until we educate them on the solution! And not many can accept there may be a better way of doing things than what they themselves have been doing for years!

What would be your top piece of advice for anyone thinking of starting up their own SME?

Starting up in business is a step that many think about doing but very few actually do. Most would be led to believe that you would need to work for months, maybe years on market research, business planning, strategy etc. before starting a business. My one piece of advice would be to start. Most of what you learn will come from doing. It is essential for entrepreneurs to fail, make the mistakes and learn what not to do next time so you have a better chance of success going forward. Many successful businesses emerge from failure.

What is it about the Flue2Chem project that is unique, what made you want to get involved, and what is the potential difference this project could make?

The Flue2Chem project is aimed at converting industrial waste gases into sustainable materials for use in consumer products. What is unique about the Flue2Chem project is that organisations that would normally be competitors have come together to find a solution for a problem that affects us all – as people, as businesses and as a planet. It is rare to see such cross-industry collaboration on this level and this allows both cross-learning and inspires others to come together, collaborate and innovate to solve problems that affect us all, much like the Flue2Chem project. It is a privilege to be part of the project by contributing our technology to the capture component.

CCU International, carbon capture technology. Image credit: Beena Sharma

The project will play a key role in supporting the UK’s 2050 net zero ambitions by providing a more sustainable feedstock for products such as household cleaning materials. The project could demonstrate how the UK could cut 15-20 million tonnes of carbon dioxide emission each year. The UK imports large quantities of carbon containing feedstocks that we use in the consumer goods industry. The project will demonstrate how we can secure an alternative domestic source of carbon for these goods and also demonstrate how industry can contribute towards achieving net zero.

Why do you think collaboration of this scale is so important?

Industry coming together to solve climate change issues is essential if we are ever to achieve net zero. Collaboration of this scale sends a strong message and emphasises that change in approach is needed and that innovation is key. This inspires others to do the same. Solutions are needed now and by bringing expertise and experience together we learn and adapt quicker. Solutions are needed now – not in years to come.

The impact this project will have has the potential to be huge, across multiple industries and certainly with how we look at not only capturing carbon emissions but also what we can do with the captured carbon dioxide, promoting a circular carbon economy where in time we learn to value carbon dioxide in a way that has never been done before.

Certainly, for the carbon capture storage community, this project will show that there is a use for captured carbon dioxide other than treating it as a waste and sequestering in underground oil reservoirs. Utilising captured carbon dioxide can create revenue streams for any business or process that emits carbon dioxide.

The collaboration demonstrates the commitment from industries to support decarbonisation, of those industries that are hard to abate whilst at the same time building a new UK value chain.

Are you interested in pharmaceutical R&D? Which PhD skills are particularly useful in industry? We asked James Douglas, Director of Global High-Throughput Experimentation at AstraZeneca.

Tell us about your career path to date.

I currently have two roles, firstly as Director of Global High-Throughput Experimentation (HTE) within R&D at the pharmaceutical company AstraZeneca. I also work one day a week as a Royal Society Entrepreneur in Residence at the Department of Chemistry in the University of Manchester. Both roles involve developing and applying methods and technology in chemical synthesis to facilitate the drug discovery, development, and manufacturing processes.

My journey to these roles began with a chemistry degree and a passion for running chemistry experiments in the laboratory. At the end of my undergraduate MChem degree at the University of York, I spent an amazing placement year at the pharmaceutical company GlaxoSmithKline, working in drug development. I then went on to do a PhD at the University of St Andrews and postdoctoral research in the USA, both of which focused on developing new methods for synthesis.

My PhD was in collaboration with AstraZeneca and my postdoc was with the pharmaceutical company Eli Lilly, so I knew a lot about medicines R&D and wanted to start a permanent career in that industry.

Pictured above: James Douglas

When did you start working for AstraZeneca?

I started at AstraZeneca in 2015. Initially, I spent most of my time working in the laboratory, supporting drug projects across a range of therapy areas such as oncology, heart disease and respiratory treatment. Since then, I have gradually spent less time in the lab across multiple roles and more time working with – and leading wider teams – with a more company-wide focus.

I have remained closely linked to academic research and universities through collaborative projects. This ultimately led me to the Entrepreneur in Residence role where I am accelerating the translation of chemistry innovation from academia to industry, as well as helping provide students and researchers skills and networks relevant to careers in industry.

What is a typical day like in your job?

I spend about two days a week on site at AstraZeneca in Macclesfield and two working from home. As my main job is office based I can also work from home very easily. It has been this way for me since the start of the pandemic. I missed the general atmosphere of a busy workplace but this period coincided with the birth of my daughter, so I feel lucky to have been able to see a lot more of her growing up than I would have otherwise.

I work with many scientists across the company, not just in Macclesfield, such as in Cambridge (UK), Boston, and Gothenburg, so virtual meetings and calls are a big part of my day. When I’m on site, I prioritise face-to face meetings and discussion with the scientists in the laboratory. Very occasionally I get the chance to run some experiments myself, which I really enjoy.

Since 2022, I have spent Fridays within the Department of Chemistry at the University of Manchester. I talk to academics and PhD students about how their research could be applied in industry, discuss current projects, and think up new ones. I’m also preparing a lecture course and organising careers and networking events to prepare students with skills that are important for careers in industry.

Which aspects of your job do you enjoy the most?

I still get the most excited when faced with the challenge of solving difficult scientific problems. This has changed during my career from working individually in the lab, on relatively clear problems during my PhD, to now being part of much larger teams trying to solve highly complex longer term challenges.

Chemistry is always advancing but so are the standards that we must push towards in drug development – for example, finding ways to shorten the time taken to bring new treatments to patients, while at the same time significantly reducing the environmental impact. That’s a daunting – but exciting – opportunity for synthetic chemists like me.

Most of all, even though the timelines are longer on the projects I work on now, there are moments of short-term success that are exciting. This could be an experimental result from the team that opens up a new possibility, or provides important insight into how best to proceed.

>> Side projects can make large waves. Dr Claire McMullin shares the insights from her journey.

What is the most challenging part of your job?

I miss being able to dedicate my time to experimental work and really understanding a problem in detail. I have spent much of my career investing the large amount of time it takes to understand a problem and think about solutions. Unfortunately, that’s no longer the case and not my main responsibility, but I still find this hard to accept!

I miss the level of detail and discussion I once had and find it a challenge not to spend all my time in the laboratory bothering all the brilliant scientists with questions about what they are doing.

How do you use the skills you obtained during your degree in your job?

Most directly, my degree gave me great general skills in chemistry, ranging from practical experimental techniques to chemical analysis and fundamental principles such as kinetics. These were the basis on which I built more specialised skills in organic synthesis during my PhD and postdoc, all of which are crucial for my career so far.

There are also lots of skills I developed that I didn’t appreciate at the time, such as time management, the ability to think independently, organisation, and teamwork. Like many others, my PhD and postdoc also taught me important lessons about resilience and perseverance.

What advice would you give others interested in pursuing a similar career path?

It’s not advice, but what worked for me was to do what I am passionate about. Don’t worry if it takes a while to work out what that exactly is. I decided to do a chemistry degree mostly because I thought I would enjoy the practical experimental side, which I did and still do. It was only during my final year placement at the pharmaceutical company GSK that I decided to do a PhD so I could learn new areas of chemistry.

Finally, it was only during my postdoc that I decided to try and solve the challenges faced with drug development in industry, rather than the more fundamental undertaken as a research group leader in academia.

I’m still finding out what things interest me and these interests keep changing. That’s the joy of disciplines like chemistry and drug development – there is always so much more to learn and challenges to overcome.

In ‘The Flowers that Bloom in the Spring’ from The Mikado, Gilbert and Sullivan were interpreting the seasons according to their 19^th Century climate – but do these flowers still, indeed, bloom in spring? The Meteorological Office’s traditional definitions of the seasons in the UK are:

• Summer from June to August
• Autumn from September to November
• Winter from December to February
• Spring from March to May

Increasingly, climate change is blurring these distinctions, and gardeners are seeing autumn stretching well towards January. Winters in maritime Great Britain are now most severe in February and March, and summer extends into September. The effects of prolonged warm autumns include accelerated growth emergence and flowering of plants which have been thought of as the harbingers of spring.

Phenological studies in the late 20^th and early 21^st Centuries established that the then-termed ‘early-spring flowering plants’ had accelerated blossoming by as much as four weeks. Now, in the second decade of the 21^st Century, it seems this is an underestimate.

Pictured above: Iris unguicularis (styllosa); the Algerian iris

Iris unguicularis (styllosa), the Algerian iris, is renowned as an early flower of spring. It now comes into bloom in late November and very early December, making it an autumn and winter flowering plant. It originates from Algeria, Greece, Turkey, Western Syria, and Tunisia and requires freely draining, light soils with minimal nutrient value. Planted in a south facing border, Iris unguicularis is an undemanding and very colourful addition to the garden. Many early-flowering plants have highly coloured flowers which attract the widest spectrum of insect pollinators.

Pictured above: Cyclamen hederifolium

Similarly, Cyclamen hederifolium (hera meaning “ivy”, folium meaning “leaf”), now flowers vigorously from mid-December, providing colour in the garden in those darkest days prior to the winter solstice. It originates from woodland, shrubland, and rocky areas in the Mediterranean region from southern France to western Turkey and on Mediterranean islands. Once the corms are established it naturalises freely, spreading by self-seeding from explosive seed capsules which cast progeny widely in borders of light, sandy nutrient-free soil.

Pictured above: alyssum (A. saxatile)

The common rockery plant alyssum (A. saxatile), is a perennial herbaceous plant, which rapidly colonises borders and will spread down onto walls providing colour from early January. It is one of the ornamental members of the cabbage family (Brassicaceae) with bright cruciform flowers.

Each of these plants is responding to climatic warming, indicating the loss of traditional seasonality. This impairs relationships between flowering plants and animal pollinators that have carefully evolved for mutual benefit over millennia. The full consequences of these losses will be apparent in years and decades to come.

Professor Geoff Dixon is author of Garden practices and their science, published by Routledge 2019.

What effect do vaping and air pollution have on your heart, and how could a light-powered pacemaker improve cardiovascular health?

It seems that every day, scientists are learning more about the factors affecting cardiovascular health and are coming up with novel ways to keep our hearts ticking for longer. Here are three interesting recent developments.

A less painful pacemaker

One of the problems with existing pacemakers is that they are implanted into the heart with one or two points of connection (using screws or hooks). According to University of Arizona researchers, when these devices detect a dangerous irregularity they send an electrical shock through the whole heart to regulate its beat.

These researchers believe their battery-free, light-powered pacemaker could improve the quality of life of heart disease patients through the increased precision of their device.

The way existing pacemakers work can be quite painful for heart disease patients.

Their pacemaker comprises a petal-like structure made from a thin flexible film (that contains light sources) and a recording electrode. Like the petals of a flower closing up at night, this mesh pacemaker envelops the heart to provide many points of contact.

The device also uses optogenetics – a biological technique to control the activity of cells using light. The researchers say this helps to control the heart far more precisely and bypass pain receptors.

‘Right now, we have to shock the whole heart to do this, [but] these new devices can do much more precise targeting, making defibrillation both more effective and less painful,’ said Igor Efimov, professor of biomedical engineering and medicine at Northwestern University.

‘Current pacemakers record basically a simple threshold, and they will tell you,’ added Philipp Gutruf, lead researcher and biomedical engineering assistant professor. ‘This is going into arrhythmia, now shock, but this device has a computer on board where you can input different algorithms that allow you to pace in a more sophisticated way.’

Another potential benefit is that the light-powered device could negate the need for battery replacement, which is done every five to seven years. That use of light to affect the heart rather than electrical signals could also mean less interference with the device’s recording capabilities and a more complete picture of cardiac episodes.

The device uses light and a technique called optogenetics, which modifies cells that are sensitive to light, then uses light to affect the behavior of those cells. Image by Philipp Gutruff.

>> See how Bright SCIdea winner Cardiatec uses AI to improve heart disease treatment.

The danger of vaping?

We don’t know a lot about the long-term effects of vaping because people simply haven’t been doing it long enough, but a recent study from the University of Wisconsin (UW) suggests that it could be bad for the heart.

Researchers selected a group of people who had used nicotine delivery devices for 4.1 years on average, those who smoked cigarettes for 23 years on average, and non-smokers and compared how their hearts behaved after smoking (the first two groups) and after exercise.

The researchers noticed differences minutes after the first two groups smoked or vaped. ‘Immediately after vaping or smoking, there were worrisome changes in blood pressure, heart rate, heart rate variability and blood vessel tone (constriction),’ said lead study author Matthew Tattersall, an assistant professor of medicine at the University of Wisconsin School of Medicine and Public Health.

The lack of long-term data means we still don’t know the effect of vaping.

Those who vaped also performed worse on the four exercise parameters compared to those who hadn’t used nicotine. Perhaps the most startling finding was the post-exercise response of those who had vaped for just four years compared to those who had smoked tobacco for 23 years.

‘The exercise performance of those who vaped was not significantly different from people who used combustible cigarettes, even though they had vaped for fewer years than the people who smoked and were much younger,’ said Christina Hughey, fellow in cardiovascular medicine at UW Health, the integrated health systems of the University of Wisconsin-Madison.

The influence of lead and air pollution

We know that smoking and passive-smoking are bad for our hearts, but some overlook the effect of other environmental toxins, especially those common to specific geographical regions.

A collaborative study including US and UK researchers has found a divergence in the types of environmental contaminants that contribute to cardiovascular ailments in both countries, aside from the prevalent smoking-related heart disease.

Hopefully, the growth in electric vehicle use will reduce air pollution

The study found that lead-related poisoning is more common in the US, whereas air pollution has a more damaging effect in the UK due mainly to increased population density. The researchers found that 6.5% of cardiovascular deaths were associated with exposure to particulate matter over the past 30 years compared to 5% in the US.

The one plus is that research has found that there has been a steady decline in cardiovascular deaths stemming from lead, smoking, secondhand smoke and air pollution over the past 30 years. Nevertheless, it will be of little comfort to those walking in the trail of exhaust fumes in cities.

‘More research on how environmental risk factors impact our daily lives is needed to help policymakers, public health experts, and communities see the big picture,’ said lead author Anoop Titus, a third-year internal medicine resident at St. Vincent Hospital in Worcester, Massachusetts.

Composts are artificial mixtures in which seeds germinate, cuttings root and whole plants grow. Their key feature is reliability of composition. The first such composts were formulated by the John Innes Centre in the 1900s. Researchers needed preparations which allowed reliable growth of plants for experiments. The main ingredients were loamy soil, sand and lime plus nutrients. John Innes composts subsequently became the mainstay of horticulturists and gardeners.

Colourful flowering in artificial composts.

Variability in the loam and its weight were major disadvantages. Scientists at the University of California solved these problems by preparing mixtures of peat, sand and nutrients. Air fill porosity characteristics of ‘UC mixes’, as they became known, allow healthy seed germination, root production, growth and flowering. Lighter weight is of major significance, allowing the easy movement of plants. Arguably, simplified transport also resulted in the advent of garden centres and freer international plant trading. As a result, the garden centre industry has become a regular social feature.

A peat extraction site.

Peat, while of major importance, is now seen as the ‘achilles heel’ of these composts. Peat bogs are very significant reservoirs for carbon dioxide and major participants in the drive for reducing the impact of climate change. The compost industry strips peat from the bogs and then mixes it into specialised formulations for seed germination or plant growth. The bogs can be reclaimed and will restart the processes of CO₂ absorption, but there is still a significant environmental penalty. Social and political pressures are driving peat reduction and its elimination from garden and commercially used composts. Peat substitutes must have the key properties of adequate air fill porosity, light weight and minimal or net zero carbon demand.

A renovated peat extraction site.

One suggestion is using coir – waste arising from coconut harvesting. Like peat, this is a natural, biodegradable product. When shredded it forms a useful peat substitute, an alternative is well composted bark and fine wood chippings, which are mixed with sand. Both are valuable composts for growing ornamental plants and germinating their seedlings. Some manufacturers are also adding loamy soil into these formulae. Problems continue, however, with finding peat-free formulae for use in commercial transplant propagation. Germinating vegetable seedlings for large scale crops requires absolute regularity and reliability. Uniform, vigorous seedlings result in mature high-quality crops suitable for once over harvesting and scheduling which meets supermarkets’ specifications.

Written by Professor Geoff Dixon, author of Garden practices and their science, published by Routledge 2019.

Rarely have science and government been as clearly linked as the initial response to the Covid-19 pandemic, when politicians could be heard claiming they were being ‘led by the science’ as often as they could be seen doing that pointing-with-a-thumb-and-fist thing.

This Thursday, the UK’s Chief Scientific Adviser, Sir Patrick Vallance, will receive the Lister Medal for his leadership during the Covid-19 pandemic, and you can stream it live here, exclusively on SCI’s YouTube channel!

In readiness for Sir Patrick’s lecture, Eoin Redahan looks back at three ways science helped to mitigate the spread of Covid-19.

People will never look at vaccine development the same way. For good or ill, we have realised just how quickly they can now be developed. Similarly, we have realised what can be achieved when the brightest brains come together. These are two of the positive legacies from Covid.

But there are others. Some of the innovations conceived to tackle Covid will now tackle other pathogens. Here are just three of the innovations that emerged…

1. Wastewater warning

As Oscar Wilde once said: ‘We are all in the gutter, but some of us are looking up at the genetic material in stool samples.’

Not many people would find inspiration in wastewater treatment plants when thinking about early warning systems for infectious diseases.

Nevertheless, during the Covid-19 pandemic, researchers at TU Darmstadt in Germany came up with a system that detected Covid infection rates in the general population by analysing their waste – a system so accurate they could detect the presence of Covid among those without recognisable symptoms.

To do this, they examined the genetic material in samples from Frankfurt’s wastewater plants and tested them using the PCR test. They claim that their measurement was so sensitive it could detect fewer than 10 confirmed Covid-19 cases per 100,000 people.

It is inevitable that Covid-19 variants will rise again, but this system could alert us to the need for tighter protective measures as soon as the virus appears in our wastewater.

2. UV air treatment

UV light can reportedly reduce indoor airborne microbes by 98%.

Warning systems are important, as are ways to stop the spread of pathogens. To do this, a team from the UK and US shed light on the problem – well, they used ultraviolet light to remove the pathogens.

Using funding from the UK Health Security Agency, Columbia University researchers discovered that far-UVC light from lights installed in the ceiling almost eliminate the indoor transmission of airborne diseases such as Covid-19 and influenza.

The researchers claim it took less than five minutes for their germicidal UV light to reduce indoor airborne microbe levels by more than 98% – and it does the job as long as the light remains switched on.

‘Far-UVC rapidly reduces the amount of active microbes in the indoor air to almost zero, making indoor air essentially as safe as outdoor air,’ said study co-author David Brenner, director of the Center for Radiological Research at Columbia University Vagelos College of Physicians and Surgeons. ‘Using this technology in locations where people gather together indoors could prevent the next potential pandemic.’

3. Biological masks?

‘Physical mask, meet biological mask.’

Many moons ago, it was strange to see a person wearing a mask, even in cities with dubious air quality. Now, they are ubiquitous, and it would appear that mask innovations are everywhere too.

During Covid, researchers from the University of Granada in Spain were aware that wearing masks for a long time could be bad for our health. They devised a near field communication tag for inside our FFP2 masks to monitor CO₂ rebreathing. This batteryless, opto-chemical sensor communicates with the wearer’s phone, telling them when CO₂ levels are too high.

In the same spirit, researchers in Helsinki, Finland, developed a ‘biological mask’ to counteract Covid-19. The University of Helsinki researchers developed a nasal spray with molecule (TRiSb92) that deactivates the coronavirus spike protein and provides short-term protection against the virus – a sort of biological mask, albeit without those annoying elastics digging into our ears.

‘In animal models, nasally administered TriSb92 offered protection against infection in an exposure situation where all unprotected mice were infected,’ said Anna Mäkelä, postdoctoral researcher and study co-author.

‘Targeting this inhibitory effect of the TriSb92 molecule to a site of the coronavirus spike protein common to all variants of the virus makes it possible to effectively inhibit the ability of all known variants.’

The idea is for this nasal spray to complement vaccines, though during peak Covid paranoia, it might be tricky persuading everyone on the bus that you’re wearing a biological mask.

Covid disrupted scientific progress for many, but as we know, invention shines through in troublesome times. Plenty of innovations such as the ones above will make us better equipped to tackle air borne diseases – alongside the stewardship of leaders like Sir Patrick Vallance.

Watch Sir Patrick Vallance’s talk – Government, Science and Industry: from Covid to Climate – at 18:25 on 24 November

How do you forge a career in process chemistry, and how do you overcome the challenges of studying in your second language? Here’s how Piera Trinchera, Associate Principal Scientist at Pharmaron, found her way.

Tell us about your career path to date.

I am an Associate Principal Scientist in the Process Chemistry department of Pharmaron UK. I am based at the Hoddesdon site in Hertfordshire, where I develop synthetic routes for the manufacture of new drugs for clinical studies.

I’m originally from Italy. I completed my MSci at the University of Salento followed by a PhD in organic chemistry at the University of Bari, focusing on new synthetic methodologies. Despite my complete lack of English at the time, I jumped at the opportunity of a six-month visiting PhD position at the University of Toronto.

This was a challenging experience initially as it was my first time living abroad, but ultimately it was very rewarding. After completing my PhD I returned to the University of Toronto to undertake a postdoctoral position focusing on organoboron chemistry. I followed this with a second postdoc at Queen Mary University of London working on aryne chemistry.

After eight years in academia, I wanted to apply the knowledge I had acquired to solving industrial problems that directly impact people’s lives. For this reason, I joined Pharmaron UK where I have been for the last three years and am currently a project lead and people manager.

What is a typical day like in your job?

I am involved in multiple projects each year and the overall aim is to provide synthetic chemistry solutions for our global clients. Depending on the type of project work, this can include either developing brand new synthetic routes to novel drug candidates or troubleshooting and improving existing chemical processes, making them suitable for large-scale manufacture.

Ultimately, the goal across all projects is the same: to support the production of large quantities of drugs that are needed for clinical studies with a line-of-sight to commercial production.

On a typical working day, I spend the majority of my time in the lab where I conduct my own experiments and lead a team of chemists who work alongside me. I am directly involved in the planning and designing of experiments, execution in the lab, and subsequent manufacture on multi-kg scale in our pilot plant.

Over the course of a project, a large part of the job is communicating to the clients the project strategy, scientific results, and timelines through regular teleconferences, emails, and written reports.

>> Read how side projects made large waves for Dr Claire McMullin

Which aspects of your job do you enjoy the most?

There are many aspects of this job that I enjoy. I have always enjoyed solving new scientific problems, with the thrill of impatiently waiting for the results of an important experiment or the curiosity in trying to understand an unexpected result.

In addition to the science, seeing your day-to-day lab work translated to the production of kg-quantities of new pharmaceutical compounds that might, after clinical studies, further global health is very rewarding.

Projects are completed on much shorter time frames than in academia (three to six months) and there is no time to stagnate as one so often does in a PhD or Postdoc. I enjoy the large breadth in the chemistry and the different challenges that come with each and every project.

Last but not least, it takes many people from different departments (e.g. in analysis, quality assurance, or manufacturing) working closely together to manufacture a drug compound on a kg-scale.

Working so closely with people from different backgrounds has tremendously enriched me during these years in Pharmaron. It has allowed me to acquire new technical knowledge and given me a deeper understanding of not just chemistry but the overall requirements for synthesising pharmaceutical compounds.

What is the most challenging part of your job?

Preparation of a synthetic process for manufacture on a kg-scale involves considerable development in the laboratory to ensure the chemistry translates from small to large scale. Part of this development is to identify potential issues and blindspots of the chemistry and processes and mitigate them by improving the process before implementation on a large scale.

Despite all these efforts, unforeseen complications do occasionally occur on the large scale and finding solutions in real time can be the most challenging aspect of the job. By keeping a clear head, the chemist can leverage both their deep knowledge of the process and the experience of their more senior colleagues to solve these problems.

How do you use the skills you obtained during your PhD and postdocs in your job?

As I’m in a synthetic chemistry job, I have benefitted enormously from the theoretical organic chemistry knowledge and practical laboratory skills that I acquired over the course of my PhD and postdoc years.

Additionally, in academia I became familiar and confident with other skills that I use on a daily basis. These include scientific communication through either written reports or oral presentations, conforming to good laboratory safety practices, and supervising and mentoring other people.

>> Get involved in the SCI Young Chemists’ Panel.

Which other skills do you need for your work?

Teamwork is a cornerstone of the job and company’s culture. The synthesis of pharmaceutical compounds according to our quality standards would not be possible without the contribution from, and close collaboration among, multiple people across several departments including analytical chemistry, process chemistry, process safety, quality assurance, formulation and manufacturing.

Is there any advice you would give to others interested in pursuing a similar career path?

Don’t be afraid to venture outside of your comfort zone and be open to opportunities, especially those that don’t come along as often. This will help you build your confidence and you will likely find that you can do more than you anticipated. If you are interested in process chemistry, I would recommend looking into internships and/or finding a mentor who can give you an insight into the job.

As with research, perseverance is an important skill you need to master. You will experience failed reactions and difficult purifications at some point in your career as a process chemist. Be open minded, ask questions and don’t be afraid to seek out support from your colleagues.

>> Read how Ofgem’s Dr Chris Unsworth creates an inclusive working environment and transfers his PhD skills.